Zuranolone: The First Pill Made for PPD

How does zuranolone work in the brain?

Zuranolone is a neuroactive steroid — a synthetic version of allopregnanolone, a calming brain chemical made from progesterone. During pregnancy, allopregnanolone rises, then falls sharply after birth, and that abrupt drop is thought to contribute to postpartum depression in vulnerable people 1Ref 1Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023).Zuranolone for the treatment of postpartum depression.The SKYLARK phase 3 trial showing oral zuranolone improved postpartum depression scores versus placebo by about day 15, with the most common effects being drowsiness and dizziness; basis for the 2023 FDA approval.. By boosting activity at the brain's GABA-A receptors, zuranolone aims to restore some of that calming signal quickly 2Ref 2Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. (2021).Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial.The ROBIN randomized trial showing zuranolone reduced depressive symptoms more than placebo in severe postpartum depression, with separation from placebo seen within days, acting through the GABA-A pathway..

This mechanism differs from selective serotonin reuptake inhibitors (SSRIs), which slowly adjust serotonin over several weeks 3Ref 3Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K (2014).Antidepressant treatment for postnatal depression.Cochrane review finding SSRIs and other antidepressants more effective than placebo for postnatal depression, with the slower onset characteristic of serotonergic medications.. Perinatal depression can begin during pregnancy and stretch across the first postpartum year, so a faster-acting option has real appeal. Understanding how postpartum depression differs from the baby blues helps frame when a medication like this is even considered.

What did the zuranolone trials show?

Two randomized trials anchor the evidence. In the 2021 ROBIN trial, women with severe postpartum depression who took zuranolone had significantly lower depression scores than those on placebo, with separation visible within 3 days 2Ref 2Deligiannidis KM, Meltzer-Brody S, Gunduz-Bruce H, et al. (2021).Effect of zuranolone vs placebo in postpartum depression: a randomized clinical trial.The ROBIN randomized trial showing zuranolone reduced depressive symptoms more than placebo in severe postpartum depression, with separation from placebo seen within days, acting through the GABA-A pathway.. The 2023 SKYLARK trial reproduced this, showing meaningful improvement within roughly 15 days, and for many, benefits that held at follow-up weeks later 1Ref 1Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023).Zuranolone for the treatment of postpartum depression.The SKYLARK phase 3 trial showing oral zuranolone improved postpartum depression scores versus placebo by about day 15, with the most common effects being drowsiness and dizziness; basis for the 2023 FDA approval..

These results led the FDA to approve zuranolone for postpartum depression in adults in 2023. According to the trial data, the most common effects were drowsiness and dizziness, which is why the labeling warns about driving 1Ref 1Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023).Zuranolone for the treatment of postpartum depression.The SKYLARK phase 3 trial showing oral zuranolone improved postpartum depression scores versus placebo by about day 15, with the most common effects being drowsiness and dizziness; basis for the 2023 FDA approval.. A Cochrane review of older antidepressants for postnatal depression found them more effective than placebo, but with slower onset 3Ref 3Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K (2014).Antidepressant treatment for postnatal depression.Cochrane review finding SSRIs and other antidepressants more effective than placebo for postnatal depression, with the slower onset characteristic of serotonergic medications..

How is it different from brexanolone and SSRIs?

Brexanolone was the first drug approved for postpartum depression, back in 2019, and it targets the same GABA pathway 4Ref 4Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. (2018).Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.Phase 3 trials of brexanolone, the first drug approved for postpartum depression, delivered as a 60-hour intravenous infusion in a monitored setting and acting on the same GABA pathway as zuranolone.. The catch is delivery: brexanolone requires a 60-hour continuous intravenous infusion in a monitored hospital setting, which limits access 4Ref 4Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. (2018).Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.Phase 3 trials of brexanolone, the first drug approved for postpartum depression, delivered as a 60-hour intravenous infusion in a monitored setting and acting on the same GABA pathway as zuranolone.. Zuranolone offers the same rapid-acting idea in a pill taken at home over 14 days.

SSRIs remain a first-line choice and are often used for longer stretches, especially when depression is ongoing rather than acute 3Ref 3Molyneaux E, Howard LM, McGeown HR, Karia AM, Trevillion K (2014).Antidepressant treatment for postnatal depression.Cochrane review finding SSRIs and other antidepressants more effective than placebo for postnatal depression, with the slower onset characteristic of serotonergic medications.. Some people take an SSRI while also weighing antidepressants during pregnancy for a future pregnancy. Zuranolone is a short course, not a maintenance medication, so clinicians often plan for what comes after the 14 days.

Who is it for, and what are the trade-offs?

Zuranolone is approved for adults with postpartum depression, and a clinician decides whether it fits a given person's history and symptoms. Cost and insurance coverage can be real barriers, and because the medication is newer, long-term and breastfeeding data are still limited 1Ref 1Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023).Zuranolone for the treatment of postpartum depression.The SKYLARK phase 3 trial showing oral zuranolone improved postpartum depression scores versus placebo by about day 15, with the most common effects being drowsiness and dizziness; basis for the 2023 FDA approval.. Because it can cause sedation, it is not combined casually with alcohol or other sedating medicines.

For someone weighing options, the link between breastfeeding and postpartum mood often comes up, since feeding plans shape medication choices. Screening matters too: the American College of Obstetricians and Gynecologists recommends screening for perinatal depression at least once in the perinatal period 5Ref 5American College of Obstetricians and Gynecologists (2018).ACOG Committee Opinion No. 757: Screening for Perinatal Depression.ACOG recommendation that clinicians screen for perinatal depression at least once during the perinatal period and ensure follow-up and treatment.. Roughly 1 in 7 people who give birth experience perinatal depression 6Ref 6National Institute of Mental Health (2023).Perinatal Depression.National overview of perinatal depression, including that it affects roughly 1 in 7 people who give birth and can occur during pregnancy or after delivery..

When postpartum depression needs a clinician

Postpartum depression is common and treatable, and it deserves a professional evaluation rather than a self-guided fix. A clinician — often an obstetric provider, primary care clinician, or behavioral health specialist — can weigh symptom severity, safety, feeding plans, and history to map out options, whether that is therapy, an SSRI, zuranolone, or a combination 5Ref 5American College of Obstetricians and Gynecologists (2018).ACOG Committee Opinion No. 757: Screening for Perinatal Depression.ACOG recommendation that clinicians screen for perinatal depression at least once during the perinatal period and ensure follow-up and treatment.. Knowing how long postpartum depression can last can set expectations for that conversation. Gale can help you prepare for it. If symptoms include thoughts of self-harm or of harming the baby, that is a reason to seek urgent help the same day rather than wait 1Ref 1Deligiannidis KM, Meltzer-Brody S, Maximos B, et al. (2023).Zuranolone for the treatment of postpartum depression.The SKYLARK phase 3 trial showing oral zuranolone improved postpartum depression scores versus placebo by about day 15, with the most common effects being drowsiness and dizziness; basis for the 2023 FDA approval..